FOCUS: PCC + Bevacizumab + CA4P Versus PCC + Bevacizumab + Placebo for Subjects With Platinum Resistant Ovarian Cancer

NCT02641639 · clinicaltrials.gov ↗
PHASE2,PHASE3
Phase
TERMINATED
Status
70
Enrollment
INDUSTRY
Sponsor class

Stopped The study was terminated early due to the lack of efficacy and the study sponsor's decision to no longer continue the study

Conditions

Interventions

Sponsor

Mateon Therapeutics